Terremoto Biosciences
Last verified 2026-04-29. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $250.0Mattributed |
|---|---|
| Latest round | series-d+, $108.0M, 2026-04-01attributed |
| Founded | unknown |
| Headquarters | South San Francisco, USA |
| Industry | bio |
| Stage | series-b+ |
| Website | terremoto.bio |
Terremoto Biosciences develops oral small-molecule drugs using novel covalent chemistry for surgical selectivity against AKT1 in cancer and hereditary hemorrhagic telangiectasia. Its covalency platform unlocks previously undruggable targets, serving patients where earlier AKT inhibitors failed on safety or durability grounds.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-01 | series-d+ | $108.0M | undisclosed |
Detected tech stack
Cloudflare, All in One SEO 4.9.7.2, All in One SEO Pack 4.9.7.2, Kinsta, Google Analytics, Google Tag Manager, Slick 1.8.1, jQuery Migrate 3.4.1, parallax.js, DoubleClick Floodlight, cdnjs, Cloudflare Bot Management
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series D+, $108.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $250.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | terremoto.bio, read 2026-04-29 |
| Description | self-reported | terremoto.bio, read 2026-04-29 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.